Nasdaq atai.

Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 million to advance multiple clinical and discovery programs.ATAI's stock price has decreased by -68.7% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 4 stock …8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated coverage of ATAI Life Sciences N.V. (NASDAQ:ATAI) with a Buy recommendation. Analyst Price Forecast Suggests 605.71% Upside. As ...

“In just four years with Florian as CEO we raised more than $600 million, grew the staff to more than 100, brought eight compounds into clinical-stage trials, and took Atai public on the Nasdaq ...May 25, 2023 · ATAI Life Sciences (NASDAQ:ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ...

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release.

Oct 2, 2023 · NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release. Nov 29, 2023 · According to 4 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,110.76% from the latest price. Find the latest analyst research for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.ATAI Stock Price | ATAI Life Sciences N.V. Stock Quote (U.S.: Nasdaq ...ATAI Life Sciences N.V. (NASDAQ:ATAI) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more ...

Apr 13, 2023 · NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.

Find real-time ATAI - ATAI Life Sciences NV stock quotes, company profile, news and forecasts from CNN Business. ... ATAI Life Sciences NV (NASDAQ:ATAI) 1.07. Delayed Data. As of 3:58pm ET -0.055 ...atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health …111.91%. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed …Nov 30, 2023 · Atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine) Aug. 08: CI Atai Life Sciences N.V., Atai Life Sciences AG Enters into the Second Amendment to Loan and Security Agreement with the Several Banks May. 31: CI Atai Life Sciences (NASDAQ:ATAI) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior business?We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.

NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R …Nov 24, 2023 · The latest ATAI Life Sciences stock prices, stock quotes, news, and ATAI history to help you invest and trade smarter. ... (NASDAQ: ATAI) reported its financial results and corporate updates for ... Atai Life Sciences (Nasdaq: ATAI) Always at the top of the list of psychedelics companies on the move, Atai Life Sciences launched a Phase 1 study of an MDMA derivative focusing on post-traumatic stress disorder in September.Mar 31, 2023 · In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. ... NASDAQ: ATAI Atai Life Sciences. Market Cap. $173M. Today's Change (-7.14% ... One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...

Based on 2 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $20.00 with a high ...

I’ve also been asked if it’s proper and ethical that COMPASS Pathways (Nasdaq: CMPS) and atai Life Sciences (Nasdaq: ATAI) own the majority of the patents around those psychedelics.Shares of Atai Life Sciences B.V. (ATAI.O), backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market ...NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.atai - encouraging results for R-ketamine As you might remember, ATAI Life Sciences AG (Nasdaq: ATAI) had a setback for R-ketamine in January this year, when the compound did not hit statistical ...Mar 27, 2023 · Over the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ... NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...First, MindMed (Nasdaq: MNMD, NEO: MMED) will present data from their Phase 2a clinical trial attempting to treat Generalized Anxiety Disorder using a large dose of LSD paired with therapy.. For serious MindMed investors, this will be a big moment. While in the short to medium-term stocks can fluctuate wildly, especially speculative biotech …

The latest price target for . ATAI Life Sciences (NASDAQ: ATAI) was reported by HC Wainwright & Co. on August 14, 2023.The analyst firm set a price target for $20.00 …

atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023.

Atai Life Sciences Nv 's revenue in 2023 is $334,000.On average, 2 Wall Street analysts forecast ATAI's revenue for 2023 to be $124,507,857, with the lowest ATAI revenue forecast at $49,803,143, and the highest ATAI revenue forecast at $199,212,571.Benzinga. Sep. 27, 2022, 02:04 PM. Atai Life Sciences' (NASDAQ:ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC ...Nov 29, 2023 · 4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price. Gainers Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) gained 34.1% to settle at $12.58 on Wednesday. ... Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 31.9% to close at $6.82 on Wednesday.Atai Life Sciences B.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the pricing of its upsized ...As of August 2, 2023, the average one-year price target for ATAI Life Sciences N.V. is 12.51. The forecasts range from a low of 5.15 to a high of $22.05. The average price target represents an ...ATAI Life Sciences N.V. Common Shares ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...

Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. CI. Nov. 14. Atai Life Sciences N.V. acquired …Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company transforming the treatment of mental health disorders. On January 12, the company announced that the Food and Drug Administration (FDA) gave the company Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R …Here are our picks for the five psychedelic companies to watch in 2022: Atai Life Sciences, Berlin, Germany – listed on NASDAQ (ATAI) since July, 2021 – Market cap $999 million. Atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is also one of the largest shareholders ...Instagram:https://instagram. banks that give you a card the same dayday trading futures strategiesgm union strikedip etf Nov 14, 2023 · Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Cash, cash ... Jun 17, 2022 · Stephen Bardin will join as CFO Designate on June 27, 2022. After a transition period, atai’s current CFO Greg Weaver will be moving into a part time strategic advisory role. NEW YORK and BERLIN ... is kaiser goodfarmland reit list NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for ... us regulated forex brokers with high leverage Atai Life Sciences N.V. (NASDAQ:ATAI) is a promising clinical-stage biopharmaceutical company that creates and funds businesses focusing on developing psychedelic-based treatments.Nov 17, 2023 · Earnings Estimate Revisions for atai Life Sciences N.V. For the fiscal year ending December 2023, this company is expected to earn -$0.81 per share, which is a change of 17.4% from the year-ago ... Over the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...